Equasens SA: Business, economic moat, 2025 performance, risks, and key metrics to watch

Equasens is not the kind of company that attracts a lot of market attention.

But sometimes the quieter businesses are the ones worth studying more closely.

It operates in healthcare IT. The company provides software and digital tools to pharmacies, doctors, nursing homes, home-care providers, hospitals, and other healthcare institutions. That puts it inside essential healthcare workflows rather than at the edge of them. This is important because software tied to daily operations, compliance, billing, and patient care is usually more resilient than software used for convenience alone.

That does not automatically make Equasens a great investment. But it does make it a business with the right starting characteristics: sticky workflows, recurring revenue, and exposure to a defensive sector.

Before we go further, a quick disclaimer: I am a shareholder of Equasens, so this is not investment advice. This is how I think through the business as an investor.

Business of Equasens

Equasens is a healthcare technology company focused on helping healthcare professionals and care institutions run their operations more efficiently.

Its business is built around five divisions.

Pharmagest is the largest and remains the core of the group. It focuses mainly on pharmacy software and related solutions.

Axigate Link serves institutions such as nursing homes, home care, and hospitals.

E-Connect provides healthcare connectivity and digital infrastructure tools.

Medical Solutions focuses on doctors and outpatient care.

Fintech is the smallest business and provides financing-related services.

The easiest way to understand Equasens is this: it started from pharmacy software, then expanded into adjacent parts of healthcare IT.

That expansion matters.

A business tied only to pharmacies may be solid, but its growth runway can be limited over time. A business that can use its installed base, healthcare expertise, and product capabilities to expand into doctors, institutions, and digital-health infrastructure has a larger opportunity set.

So the business case is not just about protecting a strong pharmacy franchise. It is also about whether Equasens can grow into a broader healthcare software platform.

How Equasens makes money

Equasens makes money from three main sources: systems and equipment, maintenance and subscriptions, and software and services.

In 2025, systems and equipment generated €94.1 million, maintenance and subscriptions generated €105.1 million, and software and services generated €37.3 million.

This revenue mix matters because it shows the company is not dependent only on one-off product sales. A meaningful part of the business is recurring. That generally leads to better revenue visibility and a more stable earnings base.

The pharmacy business remains the core earnings engine. Equasens provides software used by pharmacies for prescription processing, inventory, sales, patient management, compliance, and workflow integration.

It also sells supporting hardware and digital tools into that ecosystem. On top of that, it earns recurring revenue from maintenance, upgrades, subscriptions, and SaaS modules.

That is an attractive model.

Once the software is embedded in daily pharmacy operations, customers are less likely to switch. At the same time, recurring subscriptions and maintenance support a steadier revenue base.

Outside pharmacy, Equasens is trying to widen its earnings pool.

Axigate Link gives it exposure to nursing homes, home care, and hospitals. Medical Solutions expands its reach into doctor practice software. E-Connect adds digital identity, interoperability, and healthcare infrastructure tools. Management has also highlighted cloud, AI, and acquisitions as future growth drivers.

So when looking at Equasens, investors should not think only about the legacy pharmacy business. They should also ask whether the newer businesses can become meaningful contributors over time.

Want a concise version of Charlie Munger’s 25 human misjudgements? Download here!

Economic moat of Equasens

I would describe Equasens as a narrow-moat business.

Its strongest moat is switching cost.

Healthcare software is not something customers change casually. In a pharmacy or care setting, the software is tied to day-to-day operations. It affects billing, compliance, workflow, staff habits, integrations, and patient processes. Replacing that system creates friction, retraining costs, and operational risk. That makes customers less likely to switch unless there is a strong reason to do so.

This is where recurring revenue becomes important. Recurring revenue is not just attractive financially. It is also evidence that the software remains embedded and relevant.

The second moat source is intangible assets, though not in the typical brand-led sense.

In Equasens’ case, the intangible advantage comes from healthcare workflow knowledge, regulatory know-how, interoperability, compliance capability, and installed reputation. In healthcare IT, software needs to do more than function well. It must also fit inside a regulated and operationally sensitive environment. That creates a barrier for new entrants.

There is also some efficient scale, especially in the pharmacy core.

Specialised healthcare niches often do not support many serious competitors. Once one or two players reach scale, it becomes harder for new entrants to justify the cost of product development, customer support, compliance, and sales coverage.

What I do not see strongly is the cost advantage.

Equasens does not appear to win because it is the lowest-cost operator. It continues to invest in product, infrastructure, AI, and expansion.

I also would not make network effect a major part of the thesis.

There are ecosystem benefits from connectivity and interoperability, but this is not a classic platform business where every new user sharply increases value for the whole network.

So the moat is real, but it is not broad. It is built mainly on switching costs, regulatory fit, and embedded workflows.

Subscribe to our newsletter if you enjoy insights like this.

Equasens 2025 performance, including its debt

2025 was a solid year for Equasens.

Revenue rose to €236.5 million, up 9.1%.

ARR reached €108.0 million, up 8.8%.

Recurring EBITDA increased to €66.7 million.

Current operating income rose to €48.2 million.

Net profit came in at €41.1 million, while net profit attributable to the group was €39.3 million.

These numbers tell a simple story. The company did not just grow revenue. It also improved profitability.

The growth was also reasonably broad-based.

Pharmagest grew to €172.2 million.

Axigate Link reached €37.6 million.

E-Connect grew to €14.7 million.

Medical Solutions rose to €10.0 million.

Fintech remained small at €2.0 million and declined slightly.

That mix is worth watching.

Pharmagest is still the main engine, but the newer businesses are beginning to contribute more. Over time, investors should watch whether growth becomes more balanced across the group or remains heavily dependent on the pharmacy business.

Cash generation improved as well.

Cash flow after interest and tax rose to €56.7 million from €47.7 million a year earlier. That is encouraging because it shows the earnings are backed by real cash generation.

On debt, the balance sheet looks healthy. Equasens ended 2025 with gross cash of €136.8 million and net cash of €83.6 million, up from €79.5 million the year before.

That means this is not a leverage story. The balance sheet is not the main concern here. The more important question is whether management can continue to allocate capital well while expanding the business.

Risks of investing in Equasens

The first risk is concentration.

Even though Equasens has broadened its business, it remains heavily exposed to pharmacy software and France. That means the company is less diversified than it may first appear.

If the pharmacy market matures or growth in the core market slows, newer businesses will need to scale sufficiently to offset it.

The second risk is execution.

Equasens is trying to build a broader healthcare software platform through expansion into doctors, institutions, connectivity, AI-enabled tools, and acquisitions. That can create value, but it also creates integration risk.

Investors need to watch whether management is building a stronger and more connected platform or simply buying additional assets.

The third risk is regulatory and rollout timing.

Healthcare IT does not operate in a vacuum. Growth can depend on public systems, digital-health programmes, reimbursement structures, and implementation timelines that management cannot fully control. Even with good products and demand, revenue can be delayed if external rollout takes longer than expected.

The fourth risk is technology relevance, including AI.

AI is a risk, but I would not call it the biggest one today. The real issue is whether Equasens can keep its products useful as healthcare software evolves.

If AI becomes a real productivity tool across healthcare workflows, Equasens needs to turn its AI investments into adoption and monetisation. If it fails to do that, competitors may become more relevant over time.

The fifth risk is cybersecurity and data trust.

Healthcare software handles sensitive data. A serious breach, outage, or compliance failure can damage customer trust and create regulatory consequences. This is one of those risks that often looks small until it becomes very visible.

Key metrics to track for Equasens

As an investor, I would focus on five metrics.

ARR and recurring revenue

This is the most important metric.

ARR reached €108.0 million in 2025, up 8.8%. If ARR keeps rising steadily, it suggests the installed base remains sticky, and the shift toward recurring revenue is working.

If headline revenue grows while ARR slows meaningfully, that would make me more cautious.

Organic growth

Reported growth is useful, but not enough.

Because Equasens uses acquisitions, investors need to separate reported growth from underlying growth. Organic growth tells you whether the core business is actually improving on its own. That is much more useful than simply looking at headline revenue.

EBITDA margin

Recurring EBITDA reached €66.7 million in 2025, which implies a margin of about 28%.

This is worth tracking because it shows whether the company is growing efficiently. Revenue growth is one thing. Revenue growth with resilient margins is much more attractive.

If Equasens keeps expanding but margins weaken over time, the quality of the story becomes less compelling.

Cash conversion

Cash flow after interest and tax was €56.7 million against net profit of €41.1 million.

That is strong cash conversion. For me, this is one of the best checks on business quality. Good software companies should not only report profits. They should also turn those profits into cash.

Net cash and balance sheet strength

Equasens ended 2025 with net cash of €83.6 million.

That gives management flexibility. A strong balance sheet does not remove business risk, but it lowers financial risk and gives the company room to invest without stretching itself.

Final thoughts

Equasens is a healthcare software company with a sticky core business, growing recurring revenue, and a healthy balance sheet.

That is already a good foundation.

The real investment question is whether Equasens can become a better business over time, not just a bigger one.

If ARR continues to compound, organic growth remains healthy, margins remain resilient, cash conversion remains strong, and the balance sheet remains solid, then the investment case strengthens. If growth relies too heavily on acquisitions or newer businesses fail to scale properly, the thesis weakens.

That is the lens I would use to follow the company.

Not just whether revenue grows, but whether business quality improves.

Subscribe to our newsletter if you enjoy insights like this.